Bifurcated stent company Stentys completes $18 million ‘Series B’ venture financing
Scottish Equity Partners leads the round;
Sofinnova Partners reinvests
“This financing round will allow us to complete clinical trials and obtain CE Mark for our drug-eluting, bifurcated stent to treat coronary artery disease...”
Gonzague Issenmann, CEO, Stentys
PARIS, March 19, 2008
Medical device pioneer Stentys announced today that it has completed an $18 million ‘Series B’ round of venture financing. The lead investor was UK venture firm Scottish Equity Partners. Series A investor Sofinnova Partners also participated in the B round. Aelios Finance served as financial advisor to Stentys. Brian Kerr, one of the founding directors of Scottish Equity Partners and a Partner in the firm’s Healthcare Group, will join the Stentys Board of Directors.
Coronary artery disease, one of the leading causes of mortality in the world, is caused by fatty lesions that narrow the coronary artery and reduce blood flow, resulting in an often-lethal myocardial infarction (heart attack). Cardiologists have been using stents (small meshed metal tubes) to unclog the artery, but standard stents are simply ill-suited to treat artery bifurcations, the area where one main vessel branches out into two smaller vessels. In fact, the procedure does not work in more than one patient out of five, and these patients must subsequently undergo a second intervention, and quite often open-chest surgery.
Les commentaires récents